BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial

RESEARCH TRIANGLE PARK, N.C., May 25, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced results from a second interim analysis of its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 is a 3-part dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered once-daily (QD) BCX7353 for 28 days, as a preventative treatment to reduce the frequency of attacks in HAE patients. This second interim analysis evaluated data from all patients in Parts 1 and 2 of the trial. The first interim analysis evaluated data from 28 of 36 patients in Part 1.
 
“These data support our hypothesis regarding the initial findings seen from the first interim analysis,” said Jon Stonehouse, Chief Executive Officer & President of BioCryst. "We are delighted to see that a daily dose of 125 mg of BCX7353 results in a high level of efficacy with an improved tolerability profile compared to the 350 mg dose observed in the first interim analysis. We look forward to completing Part 3 of the trial to select appropriate doses for our pivotal program.”
Read more: BioCryst Pharmaceuticals ( BCRX )

Cannabix Technologies Adds Dr. David Hasman to Initiate Marijuana Breathalyzer Trials in British Columbia

The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety
 
VANCOUVER, BRITISH COLUMBIA--(May 25, 2017) - Cannabix Technologies Inc. (CSE:BLO)(CSE:BLO.CN)(OTC PINK:BLOZF) (the "Company or Cannabix") developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to announce that Dr. David Hasman has joined its scientific team to initiate trials in Vancouver, British Columbia. Dr. David Hasman is with Forensic Science and Technology at the British Columbia Institute of Technology (BCIT) and has been providing his expertise in the LC/MS/MS method for fentanyl and analogues for the B.C. Provincial Toxicology Centre in Vancouver.
Read more: Cannabix Technologies Inc ( BLO )

Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study

PLYMOUTH MEETING, Pa., May 24, 2017  -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV.
 
These preliminary results are from a study supported by the HIV Vaccine Trials Network (HVTN) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in collaboration with Inovio.
Read more: Inovio Pharmaceuticals ( INO )

AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma

CAMBRIDGE, Mass. --  AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), as part of the Marketing Authorization Application (MAA) review process for tivozanib as a treatment for patients with first-line renal cell carcinoma (RCC). It is expected that with the oral explanation complete, the CHMP will proceed to an opinion which they will submit to the European Commission (EC), which has the authority to approve medicines for use in the 28 countries in the European Union. The opinion is expected to be announced at a future CHMP meeting.
Read more: AVEO Oncology ( AVEO )

GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality,  Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML

Company to provide update and host conference call today on clinical data to be presented at 2017 ASCO and EHA Meetings
 
ROCKVILLE, Md. --  GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the release of abstracts containing new data from the ongoing Phase 2 clinical trial of its product candidate GMI-1271, an E-selectin antagonist, in patients with acute myeloid leukemia (AML). The data will be presented at the June annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). The data released by ASCO and EHA, which reflect a late-January analysis, will be updated in posters presented at both meetings.
Read more: GlycoMimetics Inc ( GLYC )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker